GeoVax's Chief Scientific Officer to Present at HIV Vaccine Conference
2014 Cent Gardes HIV Vaccine Conference To be Attended by Worldwide Thought Leaders in HIV Vaccines
25 September 2014 - GeoVax Labs, Inc. (OTCBB:GOVX), a biotechnology company developing HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will participate in a panel discussion on HIV vaccine clinical trials on October 7, 2014 at the 2014 Cent Gardes HIV Vaccine Conference in Veyrier du Lac, France. In the introduction to the discussion, Dr. Robinson will provide an update on GeoVax's HIV vaccine trials, "Clade B VLP expressing DNA/MVA Vaccine".
The 2014 Cent Gardes HIV Vaccine Conference (October 5-7, 2014) will be devoted to the discussion of the most promising vaccine prospects for the future, and will be attended by global experts and thought leaders in HIV vaccine research and support. Among other things, the goal of the conference is to allow high-level exchanges within the scientific community, foster comparisons between various vaccine models and strategies, create collaborative approaches and help promising approaches move forward. The conference is sponsored by Foundation Merieux.
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax's unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Priming and boosting can also be done with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. GeoVax's vaccines are currently being tested in human clinical trials, for both preventive and therapeutic applications. Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in close to 500 humans.
Certain statements in this document are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances. Actual results may
differ materially from those included in these statements due to a variety of factors, including
whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax
vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines
with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human
use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required capital to complete
vaccine development, there is development of competitive products that may be more effective,
less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable
manufacturing and distribution agreements, and other factors, over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. More information about these factors is contained in GeoVax's filings with the
Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: